There are numerous novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease, including glucagon-like peptide 1 (GLP-1) agonist, and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors [41]. Here, PCSK9 is linked to diabetes mellitus.